高级检索
当前位置: 首页 > 详情页

Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol HUST, Union Hosp, Tongji Med Coll, Dept Dermatol, Wuhan, Peoples R China [2]HUST, Sch Chem & Chem Engn, Key Lab Mat Chem Energy Convers & Storage, Minist Educ, Wuhan, Peoples R China [3]Wuhan Inst Technol, Sch Mat Sci & Engn, Hubei Key Lab Plasma Chem & Adv Mat, Wuhan, Peoples R China [4]HUST,Tongji Hosp,Tongji Med Coll,Div Child Healthcare,Dept Pediat,Wuhan,Peoples R China
出处:
ISSN:

关键词: photodynamic therapy hollow mesoporous silica nanoparticles polyethyleneimine adjuvant immunotherapy

摘要:
Nanomedicine has demonstrated great potential in enhancing cancer immunotherapy. However, nanoparticle (NP)-based immunotherapy still has limitations in inducing effective antitumor responses and inhibiting tumor metastasis. Herein, polyethylenimine (PEI) hybrid thin shell hollow mesoporous silica NPs (THMSNs) were applied as adjuvant-nanocarriers and encapsulated with very small dose of photosensitizer chlorine e6 (Ce6) to realize the synergy of photodynamic therapy (PDT)/immunotherapy. Through PEI etching, the obtained Ce6@THMSNs exhibited enhanced cellular internalization and endosome/lysosome escape, which further improved the PDT efficacy of Ce6@THMSNs in destroying tumor cells. After PDT treatment, the released tumor-associated antigens with the help of THMSNs as adjuvants promoted dendritic cells maturation, which further boosted CD8(+) cytotoxic T lymphocytes activation and triggered antitumor immune responses. The in vivo experiments demonstrated the significant potency of Ce6@THMSNs-based PDT in obliterating primary tumors and inducing persistent tumor-specific immune responses, thus preventing distant metastasis. Therefore, we offer a THMSNs-mediated and PDT-triggered nanotherapeutic system with immunogenic property, which can elicit robust antitumor immunity and is promising for future clinical development of immunotherapy.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 工程技术
小类 | 2 区 综合性期刊
最新[2025]版:
大类 | 3 区 生物学
小类 | 3 区 生物工程与应用微生物 4 区 工程:生物医学
JCR分区:
出版当年[2020]版:
Q1 MULTIDISCIPLINARY SCIENCES
最新[2024]版:
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 ENGINEERING, BIOMEDICAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol HUST, Union Hosp, Tongji Med Coll, Dept Dermatol, Wuhan, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:622 今日访问量:0 总访问量:452 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)